You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson
AstraZeneca
Harvard Business School
Dow
Moodys

Last Updated: March 31, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ERLOTINIB HYDROCHLORIDE

» See Plans and Pricing

« Back to Dashboard

505(b)(2) Clinical Trials for erlotinib hydrochloride

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
New Combination NCT00130520 Bevacizumab and Erlotinib Study in Advanced Ovarian Cancer Completed Genentech, Inc. Phase 2 2005-06-01 The purpose of this project is to determine if a new combination of drugs, erlotinib (Tarceva™) and bevacizumab is safe and effective for treating women diagnosed with ovarian cancer whose cancer has progressed while on prior standard chemotherapy treatment with a taxane (paclitaxel or docetaxel) and a platinum (cisplatin or carboplatin).
New Combination NCT00130520 Bevacizumab and Erlotinib Study in Advanced Ovarian Cancer Completed University of Arizona Phase 2 2005-06-01 The purpose of this project is to determine if a new combination of drugs, erlotinib (Tarceva™) and bevacizumab is safe and effective for treating women diagnosed with ovarian cancer whose cancer has progressed while on prior standard chemotherapy treatment with a taxane (paclitaxel or docetaxel) and a platinum (cisplatin or carboplatin).
New Combination NCT02353741 Concurrent EGFR-TKIs and Thoracic Radiation Therapy in Active EGFR Mutation for 1st Line Treatment of Stage IV NSCLC Recruiting Xinqiao Hospital of Chongqing Phase 2 2015-04-01 This single-arm phase II study aims to study the efficacy of a possible first line treatment that combines epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKIs) with concurrent thoracic radiation therapy for stage IV non-small cell lung cancer (NSCLC) with active EGFR mutation, as well as assessing PFS, OS, tumor response, etc. to verify that this new combinational therapy can benefit short-term and long-term survival of the patients with advanced NSCLC.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for erlotinib hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00026338 Gemcitabine With or Without Erlotinib in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer Completed NCIC Clinical Trials Group Phase 3 2001-08-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Biological therapies such as erlotinib use different ways to stimulate the immune system and stop cancer cells from growing. Combining chemotherapy and biological therapy may kill more tumor cells. It is not yet known if gemcitabine is more effective with or without erlotinib in treating pancreatic cancer. PURPOSE: Randomized phase III trial to determine the effectiveness of gemcitabine with and without erlotinib in treating patients who have unresectable locally advanced or metastatic pancreatic cancer.
NCT00030446 Erlotinib and Carboplatin in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed NCIC Clinical Trials Group Phase 2 2002-01-01 RATIONALE: Biological therapies such as erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining erlotinib with carboplatin may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining erlotinib and carboplatin in treating patients who have recurrent ovarian, fallopian tube, or primary peritoneal cancer.
NCT00030485 Erlotinib in Treating Patients With Locally Advanced and/or Metastatic Endometrial Cancer Completed NCIC Clinical Trials Group Phase 2 2002-01-01 RATIONALE: Biological therapies such as erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor. PURPOSE: Phase II trial to determine the effectiveness of erlotinib in treating patients who have locally advanced and/or metastatic endometrial cancer.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for erlotinib hydrochloride

Condition Name

Condition Name for erlotinib hydrochloride
Intervention Trials
Non-small Cell Lung Cancer 113
Lung Cancer 66
Carcinoma, Non-Small-Cell Lung 50
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for erlotinib hydrochloride
Intervention Trials
Carcinoma, Non-Small-Cell Lung 391
Lung Neoplasms 338
Carcinoma 81
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for erlotinib hydrochloride

Trials by Country

Trials by Country for erlotinib hydrochloride
Location Trials
Korea, Republic of 98
Australia 93
France 92
Germany 88
United Kingdom 87
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for erlotinib hydrochloride
Location Trials
California 159
Texas 143
New York 128
Florida 110
Illinois 106
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for erlotinib hydrochloride

Clinical Trial Phase

Clinical Trial Phase for erlotinib hydrochloride
Clinical Trial Phase Trials
Phase 4 19
Phase 3 87
Phase 2/Phase 3 11
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for erlotinib hydrochloride
Clinical Trial Phase Trials
Completed 385
Active, not recruiting 106
Recruiting 99
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for erlotinib hydrochloride

Sponsor Name

Sponsor Name for erlotinib hydrochloride
Sponsor Trials
National Cancer Institute (NCI) 158
Genentech, Inc. 105
Hoffmann-La Roche 71
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for erlotinib hydrochloride
Sponsor Trials
Other 756
Industry 503
NIH 159
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Dow
Boehringer Ingelheim
Johnson and Johnson
McKesson
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.